|CEO of TapImmune says technology has multiple opportunities to succeed|
|By Staff and Wire Reports|
|Tuesday, 12 April 2011 06:05|
Dr. Glynn Wilson, Chairman & CEO of TapImmune Inc. spoke to The Wall Street reporter on Monday.
in various publications, many investors are not yet as familiar with the company and what is driving the market.
"The vaccine sector as a whole is the fastest growing sector of the pharmaceutical industry," explained Wilson. "Caner vaccines in particular have great potential. What we have done is we have a technology that is broadly applicable that works on its own or works in concert with synergistic technologies. That gives us multiple opportunities to parter, in addition to persuing our own pathway. I think we have have positioned ourselves to be a leader in this area with fundamentals together with our technology."
The complete interview, which investors should find very educational and informative as both a primer and update to the company's recent and upcoming developments, can be found here: http://www.wallstreetreporter.com/2011/04/tap-immune-inc-otcbbtpiv-ceo-interview/